Angiogenic properties of human placenta-derived adherent cells and efficacy in hindlimb ischemia

Abstract

PDACs exhibited various activities consistent with angiogenesis and tissue repair, supporting the continued investigation of this cell therapy as treatment for vascular disease-related indications.

Safety and efficacy of intramuscular human placenta‐derived mesenchymal stromal‐like cells (cenplacel [PDA‐002]) in patients who have a diabetic foot ulcer with peripheral arterial disease

“…However, the patients who had an increase in ABI had a notable change following the administration of cenplacel that continued through the long-term follow-up. This durable effect that occurred shortly after dosing suggests that cenplacel could have a therapeutic effect on the peripheral vasculature similar to the observations in the pre-clinical animal model (13), and awaits confirmation in a phase 2 study.…”

“…Animals treated with cenplacel demonstrated decreased limb necrosis with enhanced vascular collateralisation effects as evidenced by enhanced perfusion when measured by Doppler-enhanced ultrasound, and by angiographic imaging of the affected limb. Histological analysis revealed enhanced maturation of blood vessels in animals treated with cenplacel (13).…”

“…In pre‐clinical studies using rodent models of hind‐limb ischaemia, cenplacel increased angiogenesis and regeneration through the induction of blood vessel formation and muscle repair, enhanced endothelial cell survival and increased blood flow . Animals treated with cenplacel demonstrated decreased limb necrosis with enhanced vascular collateralisation effects as evidenced by enhanced perfusion when measured by Doppler‐enhanced ultrasound, and by angiographic imaging of the affected limb.…”

Concise Review: Skeletal Muscle as a Delivery Route for Mesenchymal Stromal Cells

“…It is important to note that CsA blocks recipient T‐lymphocyte reactions , and compromises granulocyte migration during acute inflammation. When hMSCs are IM‐transplanted in immunocompetent animals, a short dwell time of 4–8 days has been reported by Prather et al , Francki et al , and Hamidian Jahromi et al . Exceptions are the studies by Mao et al and Shabbir et al who reported therapeutic effects for 4 weeks that may infer survival of IM‐transplanted hWJ‐MSC or pBMMSCs in immunocompetent SD‐rats and TO2 hamsters respectively, although more probably reflect the “hit‐and‐run” mechanism by which MSCs are considered to have their effects .…”

“…Similarly, Francki et al IM‐delivered placenta‐derived adherent cells, luciferase‐transduced, in the ischemia‐induced hind limb muscle of BalbC mice 24 hours after injury, and reported significant improvement in the blood flow and vascular density by 35–49 days. Furthermore, at 49 days, the injured muscle showed a reduction of inflammatory infiltrate and improvement in the structure of the regenerated muscle fibers . Beegle et al, in a similar CLI model, IM‐transplanted hBMMSCs over‐expressing VEGF in the hamstrings of immunocompromised NOD/SCID‐IL2Rγ−/− (NSG) mice.…”